These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 8182985)

  • 21. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
    Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
    Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Myelofibrosis in patients with chronic myeloid leukemia treated with interferon-alpha].
    Kumas Sotiris ; Semenova EA; Turkina AG; Zakharova AV; Domracheva EV; Khoroshko ND; Frank GA
    Arkh Patol; 2003; 65(4):9-12. PubMed ID: 14518186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression.
    Panteli K; Zagorianakou N; Bai M; Katsaraki A; Agnantis NJ; Bourantas K
    Eur J Haematol; 2004 Jun; 72(6):410-5. PubMed ID: 15128419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The bone marrow in myeloproliferative and dysmyelopoietic syndromes.
    Wolf BC; Neiman RS
    Hematol Oncol Clin North Am; 1988 Dec; 2(4):669-94. PubMed ID: 3065324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome.
    Pullarkat V; Bass RD; Gong JZ; Feinstein DI; Brynes RK
    Am J Hematol; 2003 Jan; 72(1):8-12. PubMed ID: 12508261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Vascular changes in bone marrow in blood diseases].
    Demmler K; Burkhardt R
    Med Klin; 1980 Apr; 75(9):328-32. PubMed ID: 7402170
    [No Abstract]   [Full Text] [Related]  

  • 28. Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus.
    Paquette RL; Meshkinpour A; Rosen PJ
    Medicine (Baltimore); 1994 May; 73(3):145-52. PubMed ID: 8190037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
    Kvasnicka HM; Thiele J
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens.
    Buhr T; Büsche G; Choritz H; Länger F; Kreipe H
    Am J Clin Pathol; 2003 Jan; 119(1):152-8. PubMed ID: 12520711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypocholesterolemia in myeloproliferative disorders.
    Spanos GA; Bajaj K; Rosner F
    Arch Intern Med; 1981 Jan; 141(1):137-8. PubMed ID: 6934710
    [No Abstract]   [Full Text] [Related]  

  • 32. Trilineage extramedullary myeloid cell tumor in myelodysplastic syndrome.
    Hancock JC; Prchal JT; Bennett JM; Listinsky CM
    Arch Pathol Lab Med; 1997 May; 121(5):520-3. PubMed ID: 9167610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM
    Ann Hematol; 2006 Apr; 85(4):226-32. PubMed ID: 16421727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
    Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
    Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Progress in bone marrow biopsy].
    Higo O; Amaki I
    Nihon Rinsho; 1969 Nov; 27(11):2754-62. PubMed ID: 5390438
    [No Abstract]   [Full Text] [Related]  

  • 38. Contribution of bone marrow biopsy in the diagnosis and prognosis of polycythemia vera.
    de Mascarel A
    Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):165-6. PubMed ID: 8036134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polycythaemia after myeloid metaplasia with fibrosis: an unusual sequence.
    Gardais J; Suraniti S; Fressinaud P
    Haematologica; 1992; 77(5):433-4. PubMed ID: 1483596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.